化合物 L-365260 hemihydrate T62039

Product Introduction
Bioactivity


英文名: L-365260 hemihydrate

描述: L-365260 hemihydrate 是选择性的、具有口服活性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂，Kis 值分别为 1.9 nM 和 2.0 nM。L-365260 hemihydrate 以竞争性方式与豚鼠胃泌素和脑 CCK 受体相互作用。

体外活性: L-365260 hemihydrate exhibits a similar high affinity for brain CCK-B receptors of rats, mice and man, and a lower affinity for gastrin and brain CCK-B (IC 50 =20-40 nM) receptors in dog tissues [1]. L-365260 (1 μM) hemihydrate strongly attenuates the CCK8S- and CCK4-mediated depolarization in a different neuron [2].

体内活性: L-365260 hemihydrate (0.1-30 mg/kg; p.o.) antagonizes gastrin-stimulated acid secretion in mice (ED 50 =0.03 mg/kg), rats (ED 50 =0.9 mg/kg) and guinea pigs (ED 50 =5.1 mg/kg) [1]. L-365260 hemihydrate (0.01-10 mg/kg; s.c.) enhances analgesia induced by a submaximal dose of Morphine (4 mg/kg) in rats [3]. L-365260 hemihydrate (0.2 mg/kg; s.c. twice daily for 5 days) significantly prolongs the duration of Morphine analgesia in rats [3]. Animal Model: Male Sprague-Dawley rats (300-350 g; Morphine- injected) [3]. Dosage: 0.01, 0.05, 0.1, 0.2, 0.75, 1.0, 10.0 mg/kg Administration: S.c. 10 min prior to i.p. injection of 4 mg/kg Morphine Result: Enhanced morphine analgesia.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

化合物 L-365260 hemihydrate T62039信息由TargetMol中国为您提供，如您想了解更多关于化合物 L-365260 hemihydrate T62039报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途